Kenvue Inc. $KVUE Shares Bought by Gabelli Funds LLC

Gabelli Funds LLC grew its stake in shares of Kenvue Inc. (NYSE:KVUE) by 71.2% in the 1st quarter, HoldingsChannel reports. The firm owned 724,635 shares of the company’s stock after acquiring an additional 301,350 shares during the quarter. Gabelli Funds LLC’s holdings in Kenvue were worth $12,493,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership acquired a new stake in Kenvue during the 2nd quarter worth about $6,528,000. Jump Financial LLC increased its position in shares of Kenvue by 210.6% in the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after acquiring an additional 37,170 shares in the last quarter. AXA S.A. increased its position in shares of Kenvue by 21.1% in the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after acquiring an additional 8,524 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of Kenvue by 219.1% during the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after acquiring an additional 66,930 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Kenvue by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock valued at $39,217,000 after acquiring an additional 10,885 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE KVUE opened at $19.25 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $36.97 billion, a PE ratio of 22.65, a price-to-earnings-growth ratio of 1.46 and a beta of 0.47. The company has a 50 day moving average price of $18.38 and a two-hundred day moving average price of $17.92. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $22.87.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. Kenvue’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.24 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.3%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.59% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent analyst reports. Barclays boosted their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen raised shares of Kenvue to a “buy” rating in a research report on Sunday, July 12th. Finally, UBS Group lifted their target price on shares of Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, July 16th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.